NovoCure NVCR Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's accrued expenses and other liabilities?
- NovoCure (NVCR) reported accrued expenses and other liabilities of -$219K in Q1 2026.
- How has NovoCure's accrued expenses and other liabilities changed year-over-year?
- NovoCure's accrued expenses and other liabilities increased by 90.4% year-over-year, from -$2.27M to -$219K.
- What is the long-term trend for NovoCure's accrued expenses and other liabilities?
- Over 4 years (2021 to 2025), NovoCure's accrued expenses and other liabilities has grown at a 169.4% compound annual growth rate (CAGR), from -$94K to $4.95M.